Reagent Conjugate Delivery via Sequence-Specific Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current monoclonal antibody delivery systems for therapeutic or diagnostic purposes lack specificity and efficiency, leading to prolonged exposure times, kidney damage, and non-specific distribution of radioactive isotopes, limiting their effectiveness in targeting internal sites like tumors and increasing background levels during imaging.
Innovation Solution
A multi-step delivery system using sequence-specific components, such as DNA or RNA-like polymers, to form reagent conjugates that rapidly and specifically bind to target analytes, allowing for efficient delivery of active compounds to target sites while minimizing exposure to non-target areas.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used as delivery agents, then specific binding to target sites is achieved, but prolonged exposure times and lack of specificity cause damage to untargeted tissues
Solution Approach 1:
The delivery system is divided into separate functional components: a targeting reagent (monoclonal antibody) that binds to the target site, and a carrier reagent that carries the active compound. These are linked through a bridging reagent, allowing the targeting function and delivery function to be separated and optimized independently, thereby reducing off-target effects while maintaining specificity.
Solution Approach 2:
A bridging reagent is introduced as an intermediary between the targeting reagent and the carrier reagent. This intermediary component enables specific linkage while allowing the targeting reagent to bind to the target site first, ensuring that only the active compound carried by the carrier reagent is delivered to the target, thus reducing harmful effects on untargeted tissues.
2Reliability
If monoclonal antibodies are used for delivery, then target site binding is achieved, but lengthy exposure times are required achieving optimal binding
Solution Approach 1:
The targeting reagent is administered first and allowed to bind to the target site and reach equilibrium before the carrier reagent is administered. This preliminary action ensures optimal targeting is achieved before the active compound delivery step, allowing the use of short-lived radioisotopes while still achieving optimal binding.
Solution Approach 2:
The delivery process is segmented into separate steps: first the targeting reagent binds to the target, then the carrier reagent is introduced. This segmentation allows the targeting phase to be optimized with sufficient time for equilibrium, while the delivery phase can use short-lived radioisotopes without requiring prolonged exposure.
3Reliability
If large excess of antibody conjugates is employed, then optimal binding results are achieved, but kidney damage occurs due to clearance
Solution Approach 1:
Instead of using large excesses of antibody conjugates, the system uses a controlled amount of targeting reagent that is sufficient to achieve optimal binding when linked to the carrier reagent through the bridging reagent. This partial action approach reduces the total amount of reagent that needs to be cleared by the kidneys, thereby reducing the risk of kidney damage while still achieving optimal binding results.
4Reliability
If multi-step procedure is used, then targeting specificity is improved, but device complexity increases
Solution Approach 1:
The bridging reagent serves as a modular intermediary that simplifies the multi-step procedure by providing a standardized connection mechanism between the targeting reagent and carrier reagent. This modular approach maintains the benefits of multi-step targeting while reducing the complexity through standardized components and clear sequential steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the specificity and efficiency of compound delivery to target sites, reducing background levels and exposure times, thereby improving diagnostic imaging and therapeutic outcomes by ensuring precise localization of therapeutic agents.
Implementation Method 1
Each sequence-specific component consists of an array of covalently linked units which specifically recognizes and binds to a complementary array of similar units
Data Source
AI summary
This invention relates to novel reagent conjugates and a novel multi-step process for delivering active compounds to target analytes of interest in a patient for diagnostic and therapeutic purposes. According to the process, two novel reagents are bound to each other by linkage of the sequence-specific components they contain. The first reagent, which is comprised of a target recognition component and a first sequence-specific component, is introduced into the patient and allowed to achieve maximal localization on the target cells. The second reagent, which is comprised of an active compound component and a second sequence-specific component is then introduced into the patient, thereby forming a complex with the first reagent via the recognition and binding of the sequence-specific components of the two reagents to form the reagent conjugate of the invention. The active compound component is thereby efficiently and specifically delivered to the target analyte.